Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
05:06

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

595

Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii

Petros Rafailidis1, Periklis Panagopoulos1, Christos Koutserimpas2

  • 1Second University Department of Internal Medicine, University General Hospital of Alexandroupolis, 681 00 Alexandroupolis, Greece.

Antibiotics (Basel, Switzerland)
|March 27, 2024
PubMed

Insights

Treating Acinetobacter baumannii infections is difficult due to its resistance. New antibiotics like cefiderocol offer hope against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Acinetobacter baumannii infections pose a significant global health challenge.
  • The bacterium exhibits extensive resistance mechanisms, complicating treatment.
  • Superinfections with A. baumannii have been observed during the COVID-19 pandemic.

Purpose of the Study:

  • To review therapeutic advances against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Acinetobacter baumannii infections.
  • To summarize existing information from the last decade on treatment strategies.
  • To highlight the challenges and progress in combating A. baumannii infections.

Main Methods:

  • Literature review of studies published in the last decade.
  • Analysis of antibiotic resistance profiles of A. baumannii.
  • Evaluation of the efficacy of various antimicrobial agents.

Main Results:

  • Newer beta-lactam/beta-lactamase inhibitors show limited efficacy against A. baumannii.
  • Established agents like sulbactam, polymyxins, tigecycline, and aminoglycosides are crucial for MDR/XDR infections.
  • Cefiderocol represents a valuable addition to the therapeutic armamentarium.

Conclusions:

  • Treatment of A. baumannii infections requires careful selection of antibiotics based on resistance patterns.
  • Despite challenges, therapeutic advances, including new agents like cefiderocol, are improving treatment options.
  • Continued research and development are essential to overcome antibiotic resistance in A. baumannii.
Keywords:
A. baumanniiantimicrobial resistancecefiderocolcolistinpolymyxin Bsulbactamtigecycline

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.2K
In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging09:29

In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging

Published on: April 28, 2017

9.3K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
179
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.9K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
137
Antibiotic Selection00:57

Antibiotic Selection

Overview
53.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127